Andrew James Wiele

ORCID: 0000-0002-8543-2042

MedicineBiochemistry, Genetics and Molecular BiologyEconomics, Econometrics and Finance

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies”.

Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies

The Oncologist(2021)10.1002/onco.13770

N/A

0.546DataRank · unranked

37 citations

Tharakeswara Bathala, Andrew W. Hahn, Lianchun Xiao, Munevver Duran, Jeremy A. Ross +6 more

Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma

Clinical Genitourinary Cancer(2021)10.1016/j.clgc.2021.08.007

N/A

0DataRank · unranked

36 citations

Andrew James Wiele, Devaki Shilpa Surasi, Priya Rao, Kanishka Sircar, Pheroze Tamboli +7 more